NCT06736054View on ClinicalTrials.gov

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Copper 61-PSMA PET/CT

TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.

Trial Locations (1)

92616

RECRUITING

Hoag Memorial Hospital Presbyterian, Irvine

All Listed Sponsors
lead

Hoag Memorial Hospital Presbyterian

OTHER